Tevogen Bio (TVGN) to Release Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) is projected to release its results before the market opens on Wednesday, February 25th. Analysts expect Tevogen Bio to post earnings of ($0.03) per share for the quarter.

Tevogen Bio Stock Performance

TVGN opened at $0.28 on Friday. Tevogen Bio has a 1 year low of $0.23 and a 1 year high of $1.54. The company’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $0.57. The stock has a market capitalization of $55.79 million, a PE ratio of -1.48 and a beta of -0.80.

Institutional Trading of Tevogen Bio

Large investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC boosted its stake in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period. Deutsche Bank AG lifted its holdings in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares in the last quarter.

Wall Street Analyst Weigh In

TVGN has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital cut their target price on Tevogen Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, November 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.00.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.